These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15548851)

  • 41. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
    Gunasekaran T; Gupta S; Gremse D; Karol M; Pan WJ; Chiu YL; Keith R; Fitzgerald J
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S327-35. PubMed ID: 12607793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacokinetics of lansoprazole.
    Landes BD; Petite JP; Flouvat B
    Clin Pharmacokinet; 1995 Jun; 28(6):458-70. PubMed ID: 7656504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
    Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
    Masa K; Arimori K; Nakayama T; Miyamoto S; Fujii J; Nakano M
    Biol Pharm Bull; 1999 May; 22(5):504-9. PubMed ID: 10375172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of food and antacids on lansoprazole absorption and disposition.
    Delhotal-Landes B; Cournot A; Vermerie N; Dellatolas F; Benoit M; Flouvat B
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():315-20. PubMed ID: 1820900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
    Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
    Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omeprazole and lansoprazole suspensions for nasogastric administration.
    McAndrews KL; Eastham JH
    Am J Health Syst Pharm; 1999 Jan; 56(1):81. PubMed ID: 10048885
    [No Abstract]   [Full Text] [Related]  

  • 52. A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions.
    Elshafeey AH; Elsherbiny MA; Fathallah MM
    Clin Ther; 2009 Mar; 31(3):600-8. PubMed ID: 19393850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
    Nakata H; Itoh H; Nishioka S
    J Clin Gastroenterol; 1995; 20 Suppl 2():S118-20. PubMed ID: 7594326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
    Freston JW; Pilmer BL; Chiu YL; Wang Q; Stolle JC; Griffin JS; Lee CQ
    Aliment Pharmacol Ther; 2004 May; 19(10):1111-22. PubMed ID: 15142201
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.
    Thomson AB; Sinclair P; Matisko A; Rosen E; Andersson T; Olofsson B
    Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin.
    Karol MD; Locke CS; Cavanaugh JH
    J Clin Pharmacol; 1999 Dec; 39(12):1283-9. PubMed ID: 10586395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.
    Mukherjee J; Das A; Chakrabarty US; Sahoo B; Sengupta P; Chatterjee B; Roy B; Pal TK
    Arzneimittelforschung; 2010; 60(8):506-9. PubMed ID: 20863007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity.
    Arnestad JS; Kleveland PM; Waldum HL
    Aliment Pharmacol Ther; 1997 Apr; 11(2):355-8. PubMed ID: 9146775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Eradication effect of lansoprazole-based triple therapy against H. pylori].
    Sugiyama T; Asaka M
    Nihon Rinsho; 2004 Mar; 62(3):483-8. PubMed ID: 15038091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.